Comparative proteomics analysis of human osteosarcomas and benign tumor of bone

Cancer Genetics and Cytogenetics

Volumn 198, Issue 2, 2010, Pages 97-106

  Li, Y ^a   Liang, Q ^a   Wen, Y Q ^a   Chen, L L ^a   Wang, L T ^a   Liu, Y L ^b   Luo, C Q ^a   Liang, H Z ^a   Li, M T ^b   Li, Z ^a  

^a SUN YAT SEN UNIVERSITY   (China)

^b SUN YAT SEN UNIVERSITY   (China)

Author keywords

[No Author keywords available]

Indexed keywords

ACTIN; ADENYLATE CYCLASE; ADENYLATE CYCLASE 1; ALPHA TUBULIN; ALPHA TUBULIN 1C; BETA ACTIN; BETA TUBULIN; CALCIUM BINDING PROTEIN; EZRIN; GAMMA ACTIN 1; PROTON TRANSPORTING ADENOSINE TRIPHOSPHATE SYNTHASE; RETICULOCALBIN 3; TRANSFERRIN; TUMOR MARKER; TYROSINE 3 MONOOXYGENASE; UNCLASSIFIED DRUG; VIMENTIN; ZINC FINGER PROTEIN; ZINC FINGER PROTEIN 133;

ADOLESCENT; ADULT; AMINO ACID SEQUENCE; ARTICLE; BENIGN TUMOR; CANCER GROWTH; CANCER INVASION; CARCINOGENESIS; CHONDROBLASTOMA; COMPARATIVE GENE MAPPING; CONTROLLED STUDY; DISTANT METASTASIS; DOWN REGULATION; FEMALE; GIANT CELL TUMOR; HUMAN; HUMAN TISSUE; IMMUNOHISTOCHEMISTRY; MALE; MASS SPECTROMETRY; MICROTUBULE; MOLECULAR STABILITY; OSTEOBLASTOMA; OSTEOSARCOMA; PREDICTION; PRIORITY JOURNAL; PROGNOSIS; PROTEIN EXPRESSION; PROTEOMICS; TWO DIMENSIONAL GEL ELECTROPHORESIS; UPREGULATION; WESTERN BLOTTING;

ADOLESCENT; ADULT; AGED; BONE AND BONES; BONE NEOPLASMS; CHILD; CHONDROBLASTOMA; FEMALE; GIANT CELL TUMOR OF BONE; HUMANS; MALE; MIDDLE AGED; NEOPLASM PROTEINS; OSTEOBLASTOMA; OSTEOSARCOMA; PROTEOME; PROTEOMICS; TUMOR MARKERS, BIOLOGICAL; YOUNG ADULT;

EID: 77950807916     PISSN: 01654608     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.cancergencyto.2010.01.003     Document Type: Article

References (47)

1. Sandberg A.A., Bridge J.A. Updates on the cytogenetics and molecular genetics of bone and soft tissue tumors: osteosarcoma and related tumors. Cancer Genet Cytogenet 2003, 145:1-30.
2. Ferguson W.S., Goorin A.M. Current treatment of osteosarcoma. Cancer Invest 2001, 19:292-315.
3. Marina N., Gebhardt M., Teot L., Gorlick R. Biology and therapeutic advances for pediatric osteosarcoma. Oncologist 2004, 9:422-441.
4. Selvarajah S., Yoshimoto M., Maire G., Paderova J., Bayani J., Squire J.A., Zielenska M. Identification of cryptic microaberrations in osteosarcoma by high-definition oligonucleotide array comparative genomic hybridization. Cancer Genet Cytogenet 2007, 179:52-61.
5. Sadikovic B., Yoshimoto M., Al-Romaih K., Maire G., Zielenska M., Squire J.A. In vitro analysis of integrated global high-resolution DNA methylation profiling with genomic imbalance and gene expression in osteosarcoma. PLoS One 2008, 3:e2834.
6. dos Santos Aguiar S de Jesus Girotto Zambaldi L, dos Santos AM, Pinto W Jr., Brandalise SR. Comparative genomic hybridization analysis of abnormalities in chromosome 21 in childhood osteosarcoma. Cancer Genet Cytogenet 2007, 175:35-40.
7. Bayani J., Zielenska M., Pandita A., Al-Romaih K., Karaskova J., Harrison K., Bridge J.A., Sorensen P., Thorner P., Squire J.A. Spectral karyotyping identifies recurrent complex rearrangements of chromosomes 8, 17, and 20 in osteosarcomas. Genes Chromosomes Cancer 2003, 36:7-16.
8. Ozaki T., Neumann T., Wai D., Schafer K.L., van Valen F., Lindner N., Scheel C., Böcker W., Winkelmann W., Dockhorn-Dworniczak B., Horst J., Poremba C. Chromosomal alterations in osteosarcoma cell lines revealed by comparative genomic hybridization and multicolor karyotyping. Cancer Genet Cytogenet 2003, 140:145-152.
9. Zielenska M., Marrano P., Thorner P., Pei J., Beheshti B., Ho M., Bayani J., Liu Y., Sun B.C., Squire J.A., Hao X.S. Highresolution cDNA microarray CGH mapping of genomic imbalances in osteosarcoma using formalin-fixed paraffin-embedded tissue. Cytogenet Genome Res 2004, 107:77-82.
10. Squire J.A., Pei J., Marrano P., Beheshti B., Bayani J., Lim G., Moldovan L., Zielenska M. High-resolution mapping of amplifications and deletions in pediatric osteosarcoma by use of CGH analysis of cDNA microarrays. Genes Chromosomes Cancer 2003, 38:215-225.
11. Lim G., Karaskova J., Beheshti B., Vukovic B., Bayani J., Selvarajah S., Watson S.K., Lam W.L., Zielenska M., Squire J.A. An integrated mBAND and submegabase resolution tiling set (SMRT) CGH array analysis of focal amplification, microdeletions, and ladder structures consistent with breakage-fusion-bridge cycle events in osteosarcoma. Genes Chromosomes Cancer 2005, 42:392-403.
12. Gorlick R., Anderson P., Andrulis I., Arndt C., Beardsley G.P., Bernstein M., Bridge J., Cheung N.K., Dome J.S., Ebb D., Gardner T., Gebhardt M., Grier H., Hansen M., Healey J., Helman L., Hock J., Houghton J., Houghton P., Huvos A., Khanna C., Kieran M., Kleinerman E., Ladanyi M., Lau C., Malkin D., Marina N., Meltzer P., Meyers P., Schofield D., Schwartz C., Smith M.A., Toretsky J., Tsokos M., Wexler L., Wigginton J., Withrow S., Schoenfeldt M., Anderson B. Biology of childhood osteogenic sarcoma and potential targets for therapeutic development: meeting summary. Clin Cancer Res 2003, 9:5442-5453.
13. Atiye J., Wolf M., Kaur S., Monni O., Böhling T., Kivioja A., Tas E., Serra M., Tarkkanen M., Knuutila S. Gene amplifications in osteosarcoma-CGH microarray analysis. Genes Chromosomes Cancer 2005, 42:158-163.
14. Selvarajah S., Yoshimoto M., Ludkovski O., Park P.C., Bayani J., Thorner P., Maire G., Squire J.A., Zielenska M. Genomic signatures of chromosomal instability and osteosarcoma progression detected by high resolution array CGH and interphase FISH. Cytogenet Genome Res 2008, 122:5-15.
15. Jong R., Davis A.M., Mendes M.G., Wunder J.S., Bell R.S., Kandel R. Proliferative activity (Ki-67 expression) and outcome in high grade osteosarcoma: a study of 27 cases. Sarcoma 2000, 4:47-55.
16. Bajpai J., Sharma M., Sreenivas V., Kumar R., Gamnagatti S., Khan S.A., Rastogi S., Malhotra A., Bakhshi S. VEGF expression as a prognostic marker in osteosarcoma. Pediatr Blood Cancer 2009, 53:1035-1039.
17. Sorensen F.B., Jensen K., Vaeth M., Hager H., Funder A.M., Safwat A., Keller J., Christensen M. Immunohistochemical estimates of angiogenesis, proliferative activity, p53 expression, and multiple drug resistance have no prognostic impact in osteosarcoma: a comparative clinicopathological investigation. Sarcoma 2008, 2008:874075.
18. Bacci G., Mercuri M., Longhi A., Ferrari S., Bertoni F., Versari M., Picci P. Grade of chemotherapy-induced necrosis as a predictor of local and systemic control in 881 patients with non-metastatic osteosarcoma of the extremities treated with neoadjuvant chemotherapy in a single institution. Eur J Cancer 2005, 41:2079-2085.
19. Zunino J.H., Johnston J.O. Prognostic value of histologic tumor necrosis assessment in osteogenic sarcoma of bone. Am J Orthop 2000, 29:369-372.
20. Alaiya A., Al-Mohanna M., Linder S. Clinical cancer proteomics: promises and pitfalls. J Proteome Res 2005, 4:1213-1222.
21. An H.J., Kim D.S., Park Y.K., Kim S.K., Choi Y.P., Kang S., Ding B., Cho N.H. Comparative proteomics of ovarian epithelial tumors. J Proteome Res 2006, 5:1082-1090.
22. Li C., Zhan X., Li M., Wu X., Li F., Li J., Xiao Z., Chen Z., Feng X., Chen P., Xie J., Liang S. Proteomic comparison of two-dimensional gel electrophoresis profiles from human lung squamous carcinoma and normal bronchial epithelial tissues. Genomics Proteomics Bioinformatics 2003, 1:58-67.
23. Guo Q.C., Shen J.N., Jin S., Wang J., Huang G., Zhang L.J., Huang G., Yin J.Q., Zou C.Y., Li M.T. Comparative proteomic analysis of human osteosarcoma and SV40-immortalized normal osteoblastic cell lines. Acta Pharmacol Sin 2007, 28:850-858.
24. Liu X., Zeng B., Ma J., Wan C. Comparative proteomic analysis of osteosarcoma cell and human primary cultured osteoblastic cell. Cancer Invest 2009, 27:345-352.
25. Li Y., Dang T.A., Shen J., Perlaky L., Hicks J., Murray J., Meyer W., Chintagumpala M., Lau C.C., Man T.K. Identification of a plasma proteomic signature to distinguish pediatric osteosarcoma from benign osteochondroma. Proteomics 2006, 6:3426-3435.
26. Folio C., Mora M.I., Zalacain M., Corrales F.J., Segura V., Sierrasesućmaga L., Toledo G., San-Julian M., Patiño-Garcia A. Proteomic analysis of chemonaive pediatric osteosarcomas and corresponding normal bone reveals multiple altered molecular targets. J Proteome Res 2009, 8:3882-3888.
27. Tanaka K., Iwamoto S., Gon G., Nohara T., Iwamoto M., Tanigawa N. Expression of survivin and its relationship to loss of apoptosis in breast carcinomas. Clin Cancer Res 2000, 6:127-134.
28. Marguiles A.G., Klimberg V.S., Bhattacharrya S., Gaddy D., Suva L.J. Genomics and proteomics of bone cancer. Clin Cancer Res 2006, 12:6217s-6221s.
29. Bhattacharyya S., Byrum S., Siegel E.R., Suva L.J. Proteomic analysis of bone cancer: a review of current and future developments. Expert Rev Proteomics 2007, 4:371-378.
30. Kim M.S., Song W.S., Cho W.H., Lee S.Y., Jeon D.G. Ezrin expression predicts survival in stage IIB osteosarcomas. Clin Orthop Relat Res 2007, 459:229-236.
31. Salas S., Bartoli C., Deville J.L., Gaudart J., Fina F., Calisti A., Bollini G., Curvale G., Gentet J.C., Duffaud F., Figarella-Branger D., Bouvier C. Ezrin and alpha-smooth muscle actin are immunohistochemical prognostic markers in conventional osteosarcomas. Virchows Arch 2007, 451:999-1007.
32. Korb T., Schlüter K., Enns A., Spiegel H.U., Senninger N., Nicolson G.L., Haier J. Integrity of actin fibers and microtubules influences metastatic tumor cell adhesion. Exp Cell Res 2004, 299:236-247.
33. Barra H.S., Arce C.A., Argaraña C.E. Posttranslational tyrosination/detyrosination of tubulin. Mol Neurobiol 1988, 2:133-153.
34. Mialhe A., Lafanechère L., Treilleux I., Peloux N., Dumontet C., Brémond A., Panh M.H., Payan R., Wehland J., Margolis R.L., Job D. Tubulin detyrosination is a frequent occurrence in breast cancers of poor prognosis. Cancer Res 2001, 61:5024-5027.
35. Kato C., Miyazaki K., Nakagawa A., Ohira M., Nakamura Y., Ozaki T., Imai T., Nakagawara A. Low expression of human tubulin tyrosine ligase and suppressed tubulin tyrosination/detyrosination cycle are associated with impaired neuronal differentiation in neuroblastomas with poor prognosis. Int J Cancer 2004, 112:365-375.
36. Soucek K., Kamaid A., Phung A.D., Kubala L., Bulinski J.C., Harper R.W., Eiserich J.P. Normal and prostate cancer cells display distinct molecular profiles of alpha-tubulin posttranslational modifications. Prostate 2006, 66:954-965.
37. Whipple R.A., Balzer E.M., Cho E.H., Matrone M.A., Yoon J.R., Martin S.S. Vimentin filaments support extension of tubulin-based microtentacles in detached breast tumor cells. Cancer Res 2008, 68:5678-5688.
38. Gotzmann J., Mikula M., Eger A., Schulte-Hermann R., Foisner R., Beug H., Mikulits W. Molecular aspects of epithelial cell plasticity: implications for local tumor invasion and metastasis. Mutat Res 2004, 566:9-20.
39. Tommerup N., Vissing H. Isolation and fine mapping of 16 novel human zinc finger-encoding cDNAs identify putative candidate genes for developmental and malignant disorders. Genomics 1995, 27:259-264.
40. Li H., Jie S., Zou P., Zou G. cDNA microarray analysis of chronic myeloid leukemia. Int J Hematol 2002, 75:388-393.
41. Heiskanen M.A., Bittner M.L., Chen Y., Khan J., Adler K.E., Trent J.M., Meltzer P.S. Detection of gene amplification by genomic hybridization to cDNA microarrays. Cancer Res 2000, 60:799-802.
42. Andersen K., Smith-Sørensen B., Pedersen K.B., Hovig E., Myklebost O., Fodstad Ø, Maelandsmo G.M. Interferon-gamma suppresses S100A4 transcription independently of apoptosis or cell cycle arrest. Br J Cancer 2003, 88:1995-2001.
43. Lee S.J., Lee J.R., Hahn H.S., Kim Y.H., Ahn J.H., Bae C.D., Yang J.M., Hahn M.J. PIAS1 interacts with the KRAB zinc finger protein, ZNF133, via zinc finger motifs and regulates its transcriptional activity. Exp Mol Med 2007, 39:450-457.
44. Chan C.M., Wong S.C., Lam M.Y., Hui E.P., Chan J.K., Lo E.S., Cheuk W., Wong M.C., Tsao S.W., Chan A.T. Proteomic comparison of nasopharyngeal cancer cell lines C666-1 and NP69 identifies down-regulation of annexin II and beta2-tubulin for nasopharyngeal carcinoma. Arch Pathol Lab Med 2008, 132:675-683.
45. Mozzetti S., Ferlini C., Concolino P., Filippetti F., Raspaglio G., Prislei S., Gallo D., Martinelli E., Ranelletti F.O., Ferrandina G., Scambia G. Class III beta-tubulin overexpression is a prominent mechanism of paclitaxel resistance in ovarian cancer patients. Clin Cancer Res 2005, 11:298-305.
46. Seve P., Isaac S., Trédan O., Souquet P.J., Pacheco Y., Perol M., Lafanechere L., Penet A., Peiller E.L., Dumontet C. Expression of class III beta-tubulin is predictive of patient outcome in patients with non-small cell lung cancer receiving vinorelbine-based chemotherapy. Clin Cancer Res 2005, 11:5481-5486.
47. Ranganathan S., Salazar H., Benetatos C.A., Hudes G.R. Immunohistochemical analysis of beta-tubulin isotypes in human prostate carcinoma and benign prostatic hypertrophy. Prostate 1997, 30:263-268.